28 studies found for:    Open Studies | "Plasmacytoma"
Show Display Options
Rank Status Study
1 Recruiting CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma
Condition: Extramedullary Plasmacytoma
Interventions: Drug: CDD;   Drug: CDD Plus Bortezomib
2 Not yet recruiting Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
Condition: Solitary Osseous Plasmacytoma
Interventions: Drug: ixazomib;   Drug: lenalidomide;   Drug: dexamethasone;   Drug: zoledronic acid
3 Recruiting Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
Conditions: Extramedullary Plasmacytoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Primary Systemic Amyloidosis;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: cisplatin;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: bortezomib;   Drug: thalidomide;   Drug: melphalan;   Procedure: autologous stem cell transplant
4 Recruiting Registry of Older Patients With Cancer
Conditions: Chronic Myeloproliferative Disorders;   Cognitive/Functional Effects;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:
5 Recruiting Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Nonmalignant Neoplasm
Interventions: Other: biologic sample preservation procedure;   Other: cytology specimen collection procedure
6 Recruiting 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Conditions: Brain and Central Nervous System Tumors;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Device: 3'-deoxy-3'-[18F]fluorothymidine
7 Unknown  Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy
Conditions: Brain and Central Nervous System Tumors;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Pain;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: questionnaire administration;   Procedure: acupressure therapy;   Procedure: biopsy;   Procedure: bone marrow aspiration;   Procedure: pain therapy
8 Recruiting Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Conditions: Multiple Myeloma;   Plasma Cell Neoplasm
Interventions: Drug: Group A=30-60 CrCl (mL/min);   Drug: Group B=CrCL<30 mL/min not on dialysis;   Drug: Group C=CrCL<30 mL/min and on dialysis
9 Recruiting Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Conditions: Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma;   Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine;   Drug: mycophenolate mofetil;   Procedure: stem cell transplantation;   Radiation: total body irradiation;   Drug: filgrastim
10 Unknown  Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma
Conditions: Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine;   Biological: autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine;   Biological: autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine
11 Unknown  Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Genetic: gene expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Other: platelet aggregation test
12 Unknown  Study of DNA Samples From Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Intervention: Genetic: polymorphism analysis
13 Unknown  High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: cyclophosphamide;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation
14 Unknown  Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
Conditions: Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Precancerous Condition
Interventions: Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
15 Unknown  High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation;   Radiation: yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183
16 Recruiting Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Conditions: Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: busulfan;   Drug: cyclophosphamide;   Biological: Stem cell infusion;   Radiation: Total body irradiation
17 Unknown  Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: hydroxychloroquine;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Other: mass spectrometry;   Other: pharmacological study;   Procedure: biopsy
18 Unknown  High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Biological: pegfilgrastim;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation
19 Unknown  Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: dexamethasone
20 Unknown  Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: melphalan;   Drug: pegylated liposomal doxorubicin hydrochloride

   Previous Page Studies Shown (1-20) Next Page (21-28) Show next page of results    Last Page
Indicates status has not been verified in more than two years